Ingerid Nesthus

1.5k total citations
28 papers, 879 citations indexed

About

Ingerid Nesthus is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ingerid Nesthus has authored 28 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 10 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Ingerid Nesthus's work include Multiple Myeloma Research and Treatments (8 papers), Cancer Treatment and Pharmacology (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Ingerid Nesthus is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Cancer Treatment and Pharmacology (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Ingerid Nesthus collaborates with scholars based in Norway, Sweden and Denmark. Ingerid Nesthus's co-authors include Helga Refsum, Per Magne Ueland, Jørn Schneede, A. B. Guttormsen, Ottar Nygård, Ingemar Turesson, Øystein Bruserud, Anders Waage, Toril Holien and Oddrun Elise Olsen and has published in prestigious journals such as Journal of Clinical Investigation, British Journal of Haematology and Transfusion.

In The Last Decade

Ingerid Nesthus

27 papers receiving 850 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ingerid Nesthus Norway 14 384 302 277 249 169 28 879
Chao‐Hung Ho Taiwan 19 305 0.8× 214 0.7× 67 0.2× 60 0.2× 125 0.7× 55 837
H. L. Haak Netherlands 17 1.1k 2.9× 283 0.9× 320 1.2× 235 0.9× 135 0.8× 42 1.8k
W.Y. Au China 18 328 0.9× 448 1.5× 148 0.5× 75 0.3× 106 0.6× 57 1.1k
Joel B. Levine United States 15 95 0.2× 290 1.0× 267 1.0× 99 0.4× 249 1.5× 31 1.1k
Luigi De Sio Italy 21 129 0.3× 357 1.2× 238 0.9× 108 0.4× 229 1.4× 39 1.2k
Andres O. Soriano United States 9 363 0.9× 226 0.7× 658 2.4× 40 0.2× 85 0.5× 15 1.1k
Nicola Piccirillo Italy 14 330 0.9× 176 0.6× 86 0.3× 38 0.2× 65 0.4× 67 715
Semra Dündar Türkiye 19 360 0.9× 98 0.3× 93 0.3× 156 0.6× 174 1.0× 81 1.0k
Renate Thalhammer Austria 14 393 1.0× 405 1.3× 181 0.7× 60 0.2× 95 0.6× 35 1.0k
Sevgi Kalayoğlu Beşışık Türkiye 16 255 0.7× 340 1.1× 137 0.5× 32 0.1× 98 0.6× 100 915

Countries citing papers authored by Ingerid Nesthus

Since Specialization
Citations

This map shows the geographic impact of Ingerid Nesthus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingerid Nesthus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingerid Nesthus more than expected).

Fields of papers citing papers by Ingerid Nesthus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingerid Nesthus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingerid Nesthus. The network helps show where Ingerid Nesthus may publish in the future.

Co-authorship network of co-authors of Ingerid Nesthus

This figure shows the co-authorship network connecting the top 25 collaborators of Ingerid Nesthus. A scholar is included among the top collaborators of Ingerid Nesthus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingerid Nesthus. Ingerid Nesthus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Olsen, Oddrun Elise, Karin Fahl Wader, Hanne Hella, et al.. (2015). Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Communication and Signaling. 13(1). 27–27. 124 indexed citations
2.
Akkök, Çiğdem Akalın, et al.. (2011). Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 13(10). 1259–1268. 9 indexed citations
3.
Liseth, Knut, Elisabeth Ersvær, Jenny Foss Abrahamsen, et al.. (2009). Long‐term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells. Transfusion. 49(8). 1709–1719. 36 indexed citations
4.
Gulbrandsen, Nina, Anders Waage, Peter Gimsing, et al.. (2008). A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity. Lund University Publications (Lund University). 93. 209–209. 16 indexed citations
5.
6.
Lenhoff, Stig, Martin Hjorth, Jan Westin, et al.. (2006). Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group. British Journal of Haematology. 133(4). 389–396. 51 indexed citations
7.
Sigurdardottir, Katrin Ruth, Asbjørn Digranes, Stig Harthug, et al.. (2005). A multi-centre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility. Scandinavian Journal of Infectious Diseases. 37(6-7). 455–464. 37 indexed citations
8.
Liseth, Knut, et al.. (2004). Overlevelse etter høydosebehandling med autolog stamcellestøtte. Tidsskrift for Den Norske Laegeforening. 1 indexed citations
9.
10.
Gruber, Astrid, Magnus Björkholm, Stein A. Evensen, et al.. (2003). A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leukemia Research. 27(4). 323–328. 26 indexed citations
11.
Gulbrandsen, Nina, Finn Wislöff, Lorentz Brinch, et al.. (2001). Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell Support. Medical Oncology. 18(1). 65–78. 73 indexed citations
12.
13.
Tangen, Jon‐Magnus, Finn Wislöff, Michael Abdelnoor, et al.. (1997). Survival in 86 patients, aged 15–60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990–1995. European Journal Of Haematology. 59(2). 110–114. 1 indexed citations
14.
Bruserud, Øystein, et al.. (1997). Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: studies of allostimulated interferon-γ secretion. Cancer Immunology Immunotherapy. 43(5). 275–282. 6 indexed citations
15.
Guttormsen, A. B., Per Magne Ueland, Ingerid Nesthus, et al.. (1996). Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study.. Journal of Clinical Investigation. 98(9). 2174–2183. 223 indexed citations
16.
Bruserud, Øystein, et al.. (1995). Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia.. PubMed. 9(11). 1910–20. 59 indexed citations
17.
Nesthus, Ingerid, et al.. (1987). Immune haemolytic anaemia induced by glibenclamide in selective IgA deficiency.. BMJ. 295(6594). 366–367. 2 indexed citations
18.
Nesthus, Ingerid, et al.. (1987). In vitro evaluation of the activity of Entamoeba histolytica studies on motility.. PubMed. 10(1). 11–9. 2 indexed citations
19.
Nesthus, Ingerid, Bjørn Haneberg, Johan Glette, & C. O. Solberg. (1985). The Influence of Antimicrobial Agents on Macrophage‐Associated Staphylococcus Aureus. Acta Pathologica Microbiologica Scandinavica Series B Microbiology. 93B(1-6). 189–194. 4 indexed citations
20.
Hopen, Gunnar, Ingerid Nesthus, & Ole Didrik Lærum. (1981). Fatal Carbamazepine‐Associated Hepatitis. Acta Medica Scandinavica. 210(1-6). 333–335. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chao‐Hung Ho Breakdown of academic impact, for papers by H. L. Haak Breakdown of academic impact, for papers by W.Y. Au Breakdown of academic impact, for papers by Joel B. Levine Breakdown of academic impact, for papers by Luigi De Sio Breakdown of academic impact, for papers by Andres O. Soriano Breakdown of academic impact, for papers by Nicola Piccirillo Breakdown of academic impact, for papers by Semra Dündar Breakdown of academic impact, for papers by Renate Thalhammer Breakdown of academic impact, for papers by Sevgi Kalayoğlu Beşışık
Rankless by CCL
2026